摘要
目的:观察经导管肝动脉化疗栓塞(TACE)联合索拉非尼治疗中晚期肝细胞肝癌(HCC)的初步疗效和毒性反应。方法:选取病理证实或临床诊断及符合受试标准的中晚期HCC患者17例,行TACE治疗,术后口服索拉非尼,400mg/次,每日2次,每4～6周根据REC IST标准进行肿瘤应答的评价,并记录不良反应的发生情况。结果:近期疗效无部分缓解病例,进行独立评价的12例患者中,共10例获得疾病稳定。观察时间内的患者总体存活率为76.5%。17例患者中不良反应发生率为82.3%,经相应处理后绝大多数获得明显缓解。结论:TACE联合索拉非尼治疗中晚期HCC患者有可能获得较长的生存时间和疾病稳定状态,安全性好,值得扩大病例进一步观察。
Objective：To investigate the therapeutic effect and adverse reaction of transcatheter arterial ehemoembolization （TACE） plus sorafenib on advanced hepatocelluar carcinoma. Methods：According to the test criteria, 17 patients with HCC which was pathologically conflrmedd or clinically diagnosed were enrolled and underwent TACE, and then they were administered with sorafenib （400mg for twice per day）. the tumor response was evaluated according to RECIST criteria following every 4-6 weeks, and the reverse reaction were recorded. Results：No partial remission condition were observed in these patients, and among 12 patients who were evaluated, 10 of them gain stable condition. The total survival rate of these patients was 76. 5% during the observation. The total reverse reaction rate was 82.3%, most of them were released after treatment. Conclusion：TACE combined with sorafenib has achieved stable condition in patients with advanced HCC, which provided a new therapeutic modality, and futher studies are needed to confirm the efficacy and adverse events for intermediate and advanced HCC.
出处
《临床肿瘤学杂志》
CAS
2009年第5期401-404,共4页
Chinese Clinical Oncology
关键词
肝细胞肝癌
肝动脉化疗栓塞
分子靶向治疗
索拉非尼
Hepatocelluar carcinoma
Trauscatheter arterial ehemoembolization
Molecular targeted therapy
Sorafenib
